| Literature DB >> 34426665 |
April Morrow1,2, Priscilla Chan3, Katherine M Tucker4,5, Natalie Taylor3,6.
Abstract
PURPOSE: Despite rapid advancements in genetics and genomics, referral practices remain suboptimal. This systematic review assesses the extent to which approaches from implementation science have been applied to address suboptimal genetic referral practices.Entities:
Mesh:
Year: 2021 PMID: 34426665 PMCID: PMC8629749 DOI: 10.1038/s41436-021-01272-0
Source DB: PubMed Journal: Genet Med ISSN: 1098-3600 Impact factor: 8.822
Fig. 1PRISMA flow diagram.
Following deduplication, 9505 articles were assessed against eligibility criteria, resulting in 32 articles for inclusion.
Genetic referral barriers.
| Barrier (coded to TDF domain) | Barrier descriptions |
|---|---|
| Knowledge | Provider lack of knowledge about genetics and/or referral criteria [ |
| Provider lack of knowledge about the genetic counseling referral process [ | |
| Patient lack of knowledge about the availability of genetic services [ | |
| Provider lack of knowledge about the availability of genetic services [ | |
| Patient lack of knowledge about genetic testing and potential benefits [ | |
| Provider lack of knowledge about criteria for pathology tests to guide genetic risk assessment [ | |
| Lack of provider knowledge about the genetic counseling referral process [ | |
| Skills | Difficulties communicating genetic information to patient [ |
| Limited exploration and/or documentation of patient family history [ | |
| Incomplete ordering of pathology tests (e.g., mismatch repair immunohistochemistry) [ | |
| Difficulties applying referral guidelines/criteria to identify patients at increased genetic risk [ | |
| Training provided on an ad hoc basis, resulting in unfamiliarity with referral processes [ | |
| Environmental context & resources | Lack of on-site genetic counselors [ |
| Limited availability of genetic counselors (due to clinical demands, limited resources) and subsequent long waitlists [ | |
| Lack of geographical access to genetic services [ | |
| Patient financial constraints preventing access to genetic counseling and testing [ | |
| Time required to collect a complete family history to assess genetic risk [ | |
| Administrative referral barriers (e.g., referral forms not always available in clinic, faxing process can be fraught; multiple electronic management systems and departments with limited connectivity) [ | |
| Delayed implementation of genetic screening tests (e.g., mismatch repair immunohistochemistry) [ | |
| Lack of availability among genetic staff to attend multidisciplinary team meetings [ | |
| Genetic risk assessment guidelines may be complex to interpret and unsuited to occasional use in a busy setting [ | |
| Limited access to genetic services (reason not specified) [ | |
| Time constraints and absence of primarily responsible pathologist act as a barrier to appropriate ordering of genetic screening tests [ | |
| Limited integration of genetic testing into the cancer treatment workflow [ | |
| Memory, attention, & decision processes | Inconsistent documentation of referral recommendations [ |
| Difficulty deciding which patients were eligible for genetic screening tests (e.g., mismatch repair immunohistochemistry) [ | |
| Difficulty deciding which patients warrant genetic referral [ | |
| Genetic risk assessment guidelines may be complex to interpret and unsuited to occasional use in a busy setting [ | |
| Clinicians can easily forget to refer cases for genetic screening tests (e.g., microsatellite instability testing) [ | |
| Interpreting pathology results can be difficult, making the decision-making process more difficult and less routine [ | |
| Genetic referrals can be overlooked due to competing clinical priorities [ | |
| Clinicians may not have the necessary information (e.g., immunohistochemistry reports) to make a decision about genetic referral [ | |
| Beliefs about consequences | Perception of limited clinical utility of genetic testing among providers [ |
| Lack of patient awareness about the potential benefits of genetic testing [ | |
| Beliefs about capabilities | Lack of confidence in ability to assess patients’ genetic risk or in providing genetic services [ |
| Terminology in the pathology reports can be confusing, generating the perception that it is hard to make an appropriate referral [ | |
| Emotion | Patient fear about the potential outcomes of genetic testing [ |
| Social/professional role & identity | Lack of clarity about clinician roles in the genetic risk assessment process [ |
TDF Theoretical Domains Framework.
Example intervention strategies and their mechanistic links.
| TDF domain (MoA) | Barrier description | Behavior change technique | Example intervention strategy | Reference |
|---|---|---|---|---|
| Competing clinical demands make it difficult to ensure referrals are enacted for patients at increased hereditary cancer risk | Patient navigator role developed (cancer nurses) to assist with coordination of genetic referrals. Navigators kept lists of the tumor screen-positive patients as reported by pathologists, and helped to coordinate their referrals for genetic counseling. | Miesfeldt, 2018 [ | ||
| Limited integration of genetic testing into the cancer treatment workflow; long wait times for genetic testing, workforce shortages of genetic counselors (GC), and a lack of easily available genetic counseling in clinic locations | A dedicated genetic counselor was co-located in the medical and gynecologic oncology clinic provider workroom. The genetic counselor met with providers daily and was available to see patients in real time, as needed. The genetic counselor’s contact details were supplied to all providers and they were encouraged to reach out if there was any uncertainty about genetic testing. | Rana, 2020 [ | ||
| Lack of geographical access to genetic counseling, with no on-site genetics team | Patients at a remote site could complete a family history survey via computer tablet during their oncology treatment. Information is remotely accessible by an offsite genetics team to identify and triage eligible patients. | Cohen, 2013 [ | ||
| Provider lack of understanding about the potential clinical utility of genetic testing (in the context of hereditary cancer) | Lecture series delivered to health-care providers on the topics of hereditary cancer risk assessment, genetic testing, hereditary breast–ovarian cancer, and hereditary colon cancer. | Scheuner, 2013 [ | ||
| Provider lack of knowledge about genetics and/or referral criteria | A “traffic light” classification system was developed for the most common cancer types seen in the unit, providing instruction on the indicators for genetic referral. | Moss, 2019 [ | ||
| Performing the recommended pathology genetic screening tests [e.g., microsatellite instability for colorectal cancer (CRC) cases can easily be forgotten | Pathologists were provided with monthly electronic reminders on patients meeting inclusion criteria for genetic screening. | Overbeek, 2020 [ | ||
| Numerous (sometimes conflicting) guidelines make it difficult for clinicians to decide which patients are eligible for genetic referral | Patients entered relevant personal health and family history information into an electronic form, through which a report is generated summarizing the patients genetic risk and guiding clinicians about whether or not a genetic referral is indicated | Edelman, 2014 [ | ||
| Discomfort by nongenetics health-care providers in providing genetic services (lack of knowledge & confidence) | A registered nurse shadowed a genetic counselor and attended genetic counseling sessions for observational purposes prior to offering nurse-led genetic risk assessment and testing | Cohen, 2013 [ |